Details for New Drug Application (NDA): 213026
✉ Email this page to a colleague
The generic ingredient in AMONDYS 45 is casimersen. One supplier is listed for this compound. Additional details are available on the casimersen profile page.
Summary for 213026
Tradename: | AMONDYS 45 |
Applicant: | Sarepta Theraps Inc |
Ingredient: | casimersen |
Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 213026
Generic Entry Date for 213026*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 213026
Physiological Effect | Increased Protein Synthesis |
Suppliers and Packaging for NDA: 213026
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026 | NDA | Sarepta Therapeutics, Inc. | 60923-227 | 60923-227-02 | 1 VIAL, SINGLE-USE in 1 CARTON (60923-227-02) / 2 mL in 1 VIAL, SINGLE-USE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 100MG/2ML (50MG/ML) | ||||
Approval Date: | Feb 25, 2021 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Feb 25, 2026 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Regulatory Exclusivity Expiration: | Feb 25, 2028 | ||||||||
Regulatory Exclusivity Use: | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Nov 12, 2030 | Product Flag? | Y | Substance Flag? | Y | Delist Request? |
Expired US Patents for NDA 213026
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | ⤷ Sign Up | ⤷ Sign Up |
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription